Company intelligence / Profile preview

Dermira, Inc.

Menlo Park, California, United States

Ownership: Public · LLY
Employees: ~26
Development stage: Commercial

Overview

Dermira was a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic skin conditions. Its pipeline included both late-stage clinical candidates and an FDA-approved product. The company was acquired by Eli Lilly & Co. in January 2020 to expand Lilly’s dermatology portfolio.

Therapeutic areas: Dermatology
Modalities: Small moleculesbiologics (focus on dermatology therapies)
Industry: Biotech

Drug pipeline

3 assets

lebrikizumab

Phase 3

Indications: Atopic dermatitis

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.1T
Total revenue: $23B
Enterprise value: $1.1T

Beyond the preview

Go deeper on Dermira, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermira, Inc..

Explore the full profile